Nimodipine soft gel capsules are the generic equivalent of Nimotop capsules marketed by Bayer. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage.
Jeffrey Glazer, Heritage’s president and CEO, said: “The launch of Nimodipine represents the first of several soft gelatin capsule generic products from our partnership with Banner. This product will enable Heritage’s sales team to begin supplying the Institutional/Hospital class of trade and broadens our national account coverage.”